A calcitonin gene-related peptide (CGRP) antagonist (CGRP8-37) inhibits microvascular responses induced by CGRP and capsaicin in skin.
1. The effect of the calcitonin gene-related peptide (CGRP) antagonist CGRP8-37 on responses to CGRP and other mediators was investigated in rabbit dorsal skin. 2. Blood flow changes at intradermally-injected sites were measured by a multiple site 133xenon clearance technique. CGRP8-37 had little effect on blood flow at doses up to 0.3 nmol/site, when injected alone, although a significant increase in blood flow was observed at the highest dose tested (1 nmol/site). 3. CGRP8-37 dose-dependently inhibited the increased blood flow induced by human alpha CGRP and human beta CGRP, but had no effect on equivalent vasodilator responses induced by vasoactive intestinal peptide (VIP) and prostaglandin E1 (PGE1). CGRP8-37 showed a preferential ability to inhibit alpha CGRP (IC50 0.04 nmol), when compared with beta CGRP (IC50 greater than or equal to 0.3 nmol). 4. Capsaicin, which selectively activates sensory nerves, caused a dose-dependent increase in blood flow when injected intradermally into rabbit skin. The effects of capsaicin (0.01-0.1 mumol/site) were inhibited by CGRP8-37 (0.3 nmol/site), with a partial but significant attenuation of blood flow induced by the highest dose of capsaicin. 5. Oedema formation, induced by intradermal histamine injection (3 nmol/site), was measured in rabbit skin by the local accumulation of intravenously-injected 125I-labelled albumin. Vasodilator doses of CGRP, PGE1 and capsaicin potentiated, in a synergistic manner, oedema formation induced by histamine. GRP8-37 totally inhibited the potentiating effect of CGRP, partially inhibited the synergistic effect of capsaicin, but did not affect PGE1-induced responses.6. The results suggest that capsaicin acts to release a rabbit form of CGRP in skin and that CGRP8 37 is a useful antagonist for investigating the potential of CGRP as a neurogenic mediator of inflammation.
Hughes
S R
SR
Biomedical Sciences Division, King's College, London.
Brain
S D
SD
D000527:Alprostadil / Q000494:pharmacology; D000818:Animals; D015740:Calcitonin Gene-Related Peptide / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D002211:Capsaicin / Q000494:pharmacology*; D004357:Drug Synergism; D004487:Edema / Q000139:chemically induced / Q000378:metabolism; D006632:Histamine; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D010446:Peptide Fragments / Q000494:pharmacology*; D011817:Rabbits; D012711:Serum Albumin, Radio-Iodinated; D012867:Skin / Q000098:blood supply* / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology; D014980:Xenon Radioisotopes
D010446:Peptide Fragments; D012711:Serum Albumin, Radio-Iodinated; D014665:Vasodilator Agents; D014980:Xenon Radioisotopes; C058636:calcitonin gene-related peptide (8-37); D006632:Histamine; D000527:Alprostadil; D015740:Calcitonin Gene-Related Peptide; D002211:Capsaicin